noom microdosing glp-1 expands its range with 'microdose' package Noom Med Plans & Pricing

Ozempic could crush the junk food industry

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

Herman RJ, Hayes MR, Audrain-McGovern J, Ashare RL, Schmidt HD

Theres no one specific diet that is best for weight lossmany different dietary patterns can workif they create a sustainable calorie deficit and provide enough protein, fiber, and micronutrients

Telehealth giants National brands with ad budgets, but no local presence Google can verify Affiliate sites Forbes-style "best GLP-1" lists monetizing your patients' clicks Sponsored products Compounded semaglutide shopping ads wrapped around every search "glp1 yelm wa", live: Forbes ad up top, our client #1 organic and inside the AI Overview

Patients treated with these medications can develop several skin reactions, including injection-site reactions, hypersensitivity responses, pruritus, rashes, and immune-mediated skin disorders such as psoriasis (Pso) and hidradenitis suppurativa (HS) [14,17,18,19,20]